16 completed, 5 terminated, 2 unknown, 1 withdrawn. 10 Phase 4, 5 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Completed 6, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 3 | 5 | Completed 3, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Completed 1 |
Follow Phenprocoumon: new trials by email Literature Review of Phenprocoumon trials Research Report on Phenprocoumon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany Rivaroxaban (Xarelto, BAY 59-7939), LMWH and Phenprocoumon - Venous Thromboembolism | Completed | Bayer | 22153 | 2020-07-31 | 2022-04-28 | |
| Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon Phenprocoumon, Apixaban, Rivaroxaban (Xarelto, BAY59-7939) - Atrial Fibrillation | Completed | Bayer | 64920 | 2018-06-15 | 2020-11-27 | |
| Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy CE-mark approved LAA closure devices, Acetylsalicylic acid, Clopidogrel - Atrial Fibrillation | Phase 4 | Completed | Charite University, Berlin, Germany | 912 | 2018-02-28 | 2025-12-12 |
| Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) Apixaban, Phenprocoumon - Atrial Fibrillation, End-stage Kidney Disease | Phase 3 | Completed | Atrial Fibrillation Network | 108 | 2017-06-20 | 2022-09-27 |
| Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation Edoxaban, VKA-Based Regimen - Atrial Fibrillation | Phase 3 | Completed | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 632 | 2017-03-21 | 2019-09-23 |
| Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists Rivaroxaban (Xarelto, BAY597939), Phenprocoumon (branded and generics) - Atrial Fibrillation | Completed | Bayer | 99999 | 2016-10-15 | 2017-12-26 | |
| COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials COMBO-Stent, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran, Any drug eluting stent oder bare metal sent - Stable Angina, Unstable Angina | Phase 4 | Withdrawn | IHF GmbH - Institut für Herzinfarktforschung | 2016-04-01 | 2017-02-20 | |
| Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon Dabigatranetexilate, Phenprocoumon - Atrial Fibrillation, Left Atrial Thrombosis | Phase 4 | Unknown | University of Ulm | 40 | 2015-10-01 | 2015-11-13 |
| Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy Vitamin K antagonist, Apixaban - Atrial Fibrillation | Phase 4 | Completed | Atrial Fibrillation Network | 676 | 2014-12-01 | 2017-10-20 |
| Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF) Dabigatran etexilate, Vitamin K antagonists - Atrial Fibrillation | Completed | Boehringer Ingelheim | 1506 | 2014-09-18 | 2019-04-19 | |
| Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Dabigatran etexilate, Phenprocoumon - Atrial Fibrillation or Atrial Flutter, Thrombosis of Left Atrial Appendage | Phase 2 | Terminated | Johannes Gutenberg University Mainz | 64 | 2014-07-01 | 2019-07-26 |
| BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies Phenprocoumon (Marcumar), Rivaroxaban (Xarelto, BAY-59 7939) - Atrial Fibrillation | Completed | Bayer | 647 | 2014-01-01 | 2017-01-23 | |
| A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy phenprocoumon, vemurafenib - Malignant Melanoma, Neoplasms | Phase 1 | Completed | Hoffmann-La Roche | 2 | 2013-09-01 | 2016-11-02 |
| Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD Acetylsalicylic acid, Vitamin K antagonist - Cervical Artery Dissection | Phase 3 | Completed | Stefan Engelter | 194 | 2013-09-01 | 2024-05-21 |
| Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification Rivaroxaban or Marcumar - Atrial Fibrillation or Pulmonary Embolism, Need of Long Term Oral Anticoagulation Therapy (OAT) | Phase 4 | Completed | RWTH Aachen University | 192 | 2013-07-01 | 2020-10-22 |
| Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD) Dabigatran, Phenprocoumon - Thrombosis, Bleeding | Phase 2 | Terminated | Daniel Zimpfer, MD | 16 | 2013-01-01 | 2016-08-19 |
| Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients Heparin, fondaparinux, vitamin-K antagonists, aspirin - Unsuspected Pulmonary Embolism | Completed | G. d'Annunzio University | 695 | 2012-11-01 | 2019-08-08 | |
| Antithrombotic Triple Therapy in Humans Dabigatran, Ticagrelor, ASA, Rivaroxaban, Ticagrelor, ASA, Phenprocoumon, Ticagrelor, ASA - Atrial Fibrillation, Acute Coronary Syndrome | Phase 4 | Completed | Medical University of Vienna | 60 | 2012-10-01 | 2014-03-06 |
| Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation Dabigatran, Phenprocoumon - Coronary Heart Disease, Atrial Fibrillation | Phase 4 | Terminated | Deutsches Herzzentrum Muenchen | 46 | 2011-05-01 | 2015-02-05 |
| Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation Dabigatran, Phenprocoumon - Atrial Fibrillation | Phase 4 | Completed | Deutsches Herzzentrum Muenchen | 70 | 2011-04-01 | 2013-07-02 |
Showing 20 of 24. Sign in to see all of them.
Atrial Fibrillation (15) · Neoplasms (3) · Pulmonary Embolism (3) · Venous Thromboembolism (3) · Acute Coronary Syndrome (2) · Coronary Disease (2) · Hemorrhage (2) · Venous Thrombosis (2) · Angina, Stable (1) · Angina, Unstable (1) · Atherosclerosis (1) · Atrial Flutter (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Melanoma (1)
Bayer (4) · Atrial Fibrillation Network (2) · Deutsches Herzzentrum Muenchen (2) · Boehringer Ingelheim (1) · Cantonal Hospital of St. Gallen (1) · Charite University, Berlin, Germany (1) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1) · Daniel Zimpfer, MD (1) · G. d'Annunzio University (1) · Heart and Diabetes Center North-Rhine Westfalia (1) · Hoffmann-La Roche (1) · IHF GmbH - Institut für Herzinfarktforschung (1) · Johannes Gutenberg University Mainz (1) · Medical University of Vienna (1) · RWTH Aachen University (1)
Germany (21) · Austria (4) · Italy (4) · Netherlands (4) · Spain (4) · Belgium (3) · Canada (3) · United States (3) · Denmark (2) · Switzerland (2) · United Kingdom (2) · Czechia (1) · Finland (1) · France (1) · Hungary (1)
Julinda Mehilli, MD (2) · Bernd Poetzsch, Professor (1) · Harry R. Buller, MD, PhD (1) · Heinrich Koertke, MD (1) · Holger Reinecke, Prof. Dr. (1) · Ibrahim Akin (1) · Marcello Di Nisio, MD, PhD (1) · Michael Wolzt, Prof. MD (1) · Paulus Kirchhof, Professor (1) · Peter Bernhardt, MD (1) · Pieter W. Kamphuisen, MD, PhD (1)
PMID 23299853, PMID 25211369, PMID 28500254, PMID 29663464, PMID 30206088, PMID 31116676, PMID 32725107, PMID 33249467, PMID 35135308, PMID 36335915, PMID 37897713, PMID 39910883, PMID 40946883, PMID 41849741, PMID 42459774
2014 (1), 2016 (1)